PSA screening significantly cuts risk of death from prostate cancer, review finds
BMJ 2017; 358 doi: https://doi.org/10.1136/bmj.j4120 (Published 05 September 2017) Cite this as: BMJ 2017;358:j4120- Susan Mayor
- London
Prostate specific antigen (PSA) screening is associated with a reduction in the risk of death from prostate cancer by as much as a third, a review of conflicting randomised trials has found.1
Screening for prostate cancer with PSA has been common since the late 1980s, but two trials published in 2009 found contradictory results regarding its efficacy in reducing prostate cancer deaths. The PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) in the US found low rates of prostate cancer death that did not differ significantly between men who were screened and those who were not, while the ERSPC (European Randomized …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.